Irsamla (Vortioxetine)

Vortioxetine blocks the reuptake of serotonin and modulates several serotonin receptors—acting as a 5‑HT1A agonist, 5‑HT1B partial agonist, and antagonizing 5‑HT3 and 5‑HT7 receptors. This multifaceted action increases serotonin activity in the brain, contributing to its antidepressant effect.

The dosage of Irsamla is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of vortioxetine in pregnancy and lactation has not been fully established. Healthcare providers should weigh the potential benefits against possible risks before prescribing Irsamla to pregnant or nursing women.

To request Irsamla, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irsamla’s vortioxetine offers a unique mechanism that combines serotonin reuptake inhibition with receptor modulation, which may result in a different side‑effect profile compared with traditional SSRIs or SNRIs. Clinicians consider individual patient response, tolerability and specific symptom targets when choosing among antidepressants.

Irsamla should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability.

Irsamla is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with water and not chewed or crushed.

Serious risks include the potential for serotonin syndrome when combined with other serotonergic agents, emergence of suicidal thoughts or behaviors, severe hyponatremia, allergic reactions, and QT interval prolongation. Patients should be monitored closely for these events.

Irsamla is contraindicated in patients who are currently taking monoamine oxidase inhibitors, have a known hypersensitivity to vortioxetine, or have a history of severe serotonin syndrome. Caution is advised for individuals with uncontrolled bipolar disorder or significant liver impairment.